Zinc-based radioenhancers to activate tumor radioimmunotherapy by PD-L1 and cGAS-STING pathway
Authors:
Open Access
- 19 December 2024
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-14
Abstract
Radiotherapy and immunotherapy have already become the primary form of treatment for non-small-cell lung cancer (NSCLC), but are limited by high radiotherapy dose and low immune response rate. Herein, a multi-pronged strategy using a radio-immuno-enhancer (ZnO–Au@mSiO2) is developed by inducing tumor cells apoptosis and reprograming the immunosuppressive tumor microenvironment (TME). The radio-immuno-enhancer employed Au as a radiosensitizer, transition Zn ions as immune activators, which not only tremendously enhances the anti-proliferative activity of radiotherapy toward cancer cells, but also activates the immune response with multi-targets to let “exhausted” T cells “back to life” by triggering immunogenic cell death (ICD), immune checkpoint blockade (ICB) that target PD-1/PD-L1 and cGAS-STING under X-ray irradiation with a low dosage. The in vivo results demonstrate desirable antitumor and immunogenic effects of radio-immuno-enhancer-mediated immune activation by increasing the ratio of cytotoxic T cells (CTLs) and helper T cells. This work provides a feasible approach for future development of effective transition metal ion-activated radio-immunotherapeutic agents.Keywords
Funding Information
- the Joint Funds for the innovation of science and Technology, Fujian province (2021Y9022)
- Open Funds of Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy (NPC2023-01)
- National Natural Science Foundation of China (82172007, 81771977)
- the Science Fund for Distinguished Young Scholars of Fujian Province (2021J06007)
- Key Clinical Specialty Discipline Construction Program of Fujian,P.R.C ([(2022)884#])
This publication has 57 references indexed in Scilit:
- A Peritumorally Injected Immunomodulating Adjuvant Elicits Robust and Safe Metalloimmunotherapy against Solid TumorsAdvanced Materials, 2022
- Precisely Targeted Nano‐Controller of PD‐L1 Level for Non‐Small Cell Lung Cancer Spinal Metastasis ImmunotherapyAdvanced Healthcare Materials, 2022
- Herpesvirus‐Mimicking DNAzyme‐Loaded Nanoparticles as a Mitochondrial DNA Stress Inducer to Activate Innate Immunity for Tumor TherapyAdvanced Materials, 2022
- High‐Z‐Sensitized Radiotherapy Synergizes with the Intervention of the Pentose Phosphate Pathway for In Situ Tumor VaccinationAdvanced Materials, 2022
- Anti‐PD‐L1 DNAzyme Loaded Photothermal Mn2+/Fe3+ Hybrid Metal‐Phenolic Networks for Cyclically Amplified Tumor Ferroptosis‐ImmunotherapyAdvanced Healthcare Materials, 2021
- ZnS@BSA Nanoclusters Potentiate Efficacy of Cancer ImmunotherapyAdvanced Materials, 2021
- Self‐Assembly of Copper–DNAzyme Nanohybrids for Dual‐Catalytic Tumor TherapyAngewandte Chemie International Edition, 2021
- Target Self‐Enhanced Selectivity in Metal‐Specific DNAzymesAngewandte Chemie International Edition, 2019
- DNAzyme‐Loaded Metal–Organic Frameworks (MOFs) for Self‐Sufficient Gene TherapyAngewandte Chemie International Edition, 2019
- Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future OutlookAdvanced Materials, 2017